Cytokinetics (CYTK) is down 7.7% today. Here is some analysis on what might have caused this price movement. ([nasdaq.com](https://www.nasdaq.com/press-release/cytokinetics-announces-positive-results-acacia-hcm-presented-hot-line-session))
Analysis: The most likely explanation is a sell-the-news reaction after Cytokinetics released full Phase 3 ACACIA-HCM data for aficamten in non-obstructive hypertrophic cardiomyopathy. The study hit both dual primary endpoints, but the next major milestone is only a supplemental FDA filing planned for the fourth quarter of 2026, and investors may also be focusing on treatment interruptions tied to reduced ejection fraction and two serious heart-failure adverse events seen earlier in the program. This could be because traders had already priced in much of the clinical success after the positive topline readout in May. ([nasdaq.com](https://www.nasdaq.com/press-release/cytokinetics-announces-positive-results-acacia-hcm-presented-hot-line-session))
Details:
Sources:
Cytokinetics Investor Relations, SEC, American College of Cardiology
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 50 times in the past 6 months. Of those trades, 0 have been purchases and 50 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 14 sales selling 121,140 shares for an estimated $8,524,502.
- ROBERT I BLUM (President & CEO) has made 0 purchases and 14 sales selling 119,532 shares for an estimated $8,319,747.
- SUNG LEE (EVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 71,817 shares for an estimated $5,695,855.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 13 sales selling 47,440 shares for an estimated $3,349,793.
- JOHN T HENDERSON sold 20,000 shares for an estimated $1,519,400
- B LYNNE PARSHALL sold 5,000 shares for an estimated $370,400
- WENDELL WIERENGA sold 4,032 shares for an estimated $302,400
- EDWARD M. MD KAYE sold 2,933 shares for an estimated $223,171
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CYTK Hedge Fund Activity
We have seen 336 institutional investors add shares of $CYTK stock to their portfolio, and 188 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 9,328,094 shares (+99.3%) to their portfolio in Q2 2026, for an estimated $794,660,327
- FMR LLC removed 5,691,358 shares (-53.1%) from their portfolio in Q2 2026, for an estimated $484,846,788
- BLACKROCK, INC. added 3,546,351 shares (+21.4%) to their portfolio in Q2 2026, for an estimated $302,113,641
- AVORO CAPITAL ADVISORS LLC added 1,666,666 shares (+50.0%) to their portfolio in Q2 2026, for an estimated $141,983,276
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,603,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $136,597,223
- JPMORGAN CHASE & CO added 1,588,895 shares (+inf%) to their portfolio in Q2 2026, for an estimated $135,357,965
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,565,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $133,388,883
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 11 analysts offer price targets for $CYTK in the last 6 months, with a median target of $105.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $117.0 on 07/07/2026
- Ashwani Verma from UBS set a target price of $115.0 on 06/29/2026
- Salim Syed from Mizuho set a target price of $118.0 on 06/24/2026
- Serge Belanger from Needham set a target price of $102.0 on 06/17/2026
- Eric Joseph from Citigroup set a target price of $99.0 on 05/19/2026
- Tessa Romero from JP Morgan set a target price of $97.0 on 05/12/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $140.0 on 05/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
